Floatz logo

FULVESTRANT

PIK3CA Mutation

Relay Therapeutics, Inc.Small moleculePhase 3Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the PIK3CA Mutation cohort.

Asset / SponsorPhaseRating
Benzamide, N-[(3R)-3-(2-chloro-5-fluorophenyl)-6-(5-cyano[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2,3-dihydro-1-oxo-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)-
Relay Therapeutics, Inc.
Phase 3BB
Capivasertib
Relay Therapeutics, Inc.
Phase 3B
Palbociclib
Relay Therapeutics, Inc.
Phase 1CC
Letrozole
Relay Therapeutics, Inc.
Phase 1CC
Abemaciclib
Relay Therapeutics, Inc.
Phase 1CC

View all 16 →

Same molecule, other indications

FULVESTRANT is also rated in:

Hormone Receptor Positive TumorDormant
BB
Indicative ·
70 / 100
View asset →
hormone receptor-positive breast cancerDormant
BB
Indicative ·
70 / 100
View asset →
Progesterone Receptor PositiveDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →